S&P 500   3,345.22 (+0.52%)
DOW   27,354.87 (+0.56%)
QQQ   274.12 (+1.13%)
AAPL   455.22 (+3.40%)
MSFT   215.29 (+1.10%)
FB   264.95 (+6.35%)
GOOGL   1,504.19 (+1.70%)
AMZN   3,233.63 (+0.89%)
NVDA   453.05 (+0.35%)
CGC   17.85 (-7.08%)
BABA   264.26 (-0.25%)
TSLA   1,504.47 (+1.31%)
MU   48.97 (-4.07%)
GE   6.34 (-0.94%)
AMD   86.54 (+1.44%)
T   29.84 (-0.03%)
F   6.94 (-0.29%)
ACB   10.23 (-4.48%)
GILD   68.93 (-0.10%)
NFLX   508.36 (+1.24%)
DIS   131.18 (+2.80%)
BAC   25.44 (+0.20%)
BA   172.61 (-0.96%)
S&P 500   3,345.22 (+0.52%)
DOW   27,354.87 (+0.56%)
QQQ   274.12 (+1.13%)
AAPL   455.22 (+3.40%)
MSFT   215.29 (+1.10%)
FB   264.95 (+6.35%)
GOOGL   1,504.19 (+1.70%)
AMZN   3,233.63 (+0.89%)
NVDA   453.05 (+0.35%)
CGC   17.85 (-7.08%)
BABA   264.26 (-0.25%)
TSLA   1,504.47 (+1.31%)
MU   48.97 (-4.07%)
GE   6.34 (-0.94%)
AMD   86.54 (+1.44%)
T   29.84 (-0.03%)
F   6.94 (-0.29%)
ACB   10.23 (-4.48%)
GILD   68.93 (-0.10%)
NFLX   508.36 (+1.24%)
DIS   131.18 (+2.80%)
BAC   25.44 (+0.20%)
BA   172.61 (-0.96%)
S&P 500   3,345.22 (+0.52%)
DOW   27,354.87 (+0.56%)
QQQ   274.12 (+1.13%)
AAPL   455.22 (+3.40%)
MSFT   215.29 (+1.10%)
FB   264.95 (+6.35%)
GOOGL   1,504.19 (+1.70%)
AMZN   3,233.63 (+0.89%)
NVDA   453.05 (+0.35%)
CGC   17.85 (-7.08%)
BABA   264.26 (-0.25%)
TSLA   1,504.47 (+1.31%)
MU   48.97 (-4.07%)
GE   6.34 (-0.94%)
AMD   86.54 (+1.44%)
T   29.84 (-0.03%)
F   6.94 (-0.29%)
ACB   10.23 (-4.48%)
GILD   68.93 (-0.10%)
NFLX   508.36 (+1.24%)
DIS   131.18 (+2.80%)
BAC   25.44 (+0.20%)
BA   172.61 (-0.96%)
S&P 500   3,345.22 (+0.52%)
DOW   27,354.87 (+0.56%)
QQQ   274.12 (+1.13%)
AAPL   455.22 (+3.40%)
MSFT   215.29 (+1.10%)
FB   264.95 (+6.35%)
GOOGL   1,504.19 (+1.70%)
AMZN   3,233.63 (+0.89%)
NVDA   453.05 (+0.35%)
CGC   17.85 (-7.08%)
BABA   264.26 (-0.25%)
TSLA   1,504.47 (+1.31%)
MU   48.97 (-4.07%)
GE   6.34 (-0.94%)
AMD   86.54 (+1.44%)
T   29.84 (-0.03%)
F   6.94 (-0.29%)
ACB   10.23 (-4.48%)
GILD   68.93 (-0.10%)
NFLX   508.36 (+1.24%)
DIS   131.18 (+2.80%)
BAC   25.44 (+0.20%)
BA   172.61 (-0.96%)
Log in

NASDAQ:CNATConatus Pharmaceuticals Stock Price, Forecast & News

$2.83
-0.11 (-3.74 %)
(As of 08/6/2020 02:51 PM ET)
Add
Compare
Today's Range
$2.76
Now: $2.83
$2.95
50-Day Range
$0.56
MA: $3.08
$4.30
52-Week Range
$0.23
Now: $2.83
$1.07
Volume29,447 shs
Average Volume1.28 million shs
Market Capitalization$93.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.
Read More
Conatus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNAT
CUSIPN/A
Phone858-376-2600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.72 million
Book Value$0.53 per share

Profitability

Net Income$-11,390,000.00

Miscellaneous

Employees30
Market Cap$93.87 million
Next Earnings DateN/A
OptionableOptionable
$2.83
-0.11 (-3.74 %)
(As of 08/6/2020 02:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNAT News and Ratings via Email

Sign-up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions

How has Conatus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Conatus Pharmaceuticals' stock was trading at $0.3418 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CNAT stock has increased by 728.0% and is now trading at $2.83.
View which stocks have been most impacted by Coronavirus
.

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) issued its earnings results on Friday, May, 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.10). Conatus Pharmaceuticals had a negative return on equity of 48.22% and a negative net margin of 52.42%.
View Conatus Pharmaceuticals' earnings history
.

Has Conatus Pharmaceuticals been receiving favorable news coverage?

News coverage about CNAT stock has trended somewhat positive on Thursday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Conatus Pharmaceuticals earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Conatus Pharmaceuticals
.

Who are some of Conatus Pharmaceuticals' key competitors?

What other stocks do shareholders of Conatus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), Cascadian Therapeutics (CASC), Vaxart (VXRT), Antares Pharma (ATRS), Novavax (NVAX), Dextera Surgical (DXTR), Geron (GERN) and Verastem (VSTM).

Who are Conatus Pharmaceuticals' key executives?

Conatus Pharmaceuticals' management team includes the following people:
  • Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 67)
  • Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 51)
  • Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 64)
  • Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 61)
  • Mr. Alan R. Engbring, Exec. Director of Investor Relations & Corp. Communications

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

How do I buy shares of Conatus Pharmaceuticals?

Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Conatus Pharmaceuticals' stock price today?

One share of CNAT stock can currently be purchased for approximately $2.83.

How big of a company is Conatus Pharmaceuticals?

Conatus Pharmaceuticals has a market capitalization of $93.87 million and generates $21.72 million in revenue each year. Conatus Pharmaceuticals employs 30 workers across the globe.

What is Conatus Pharmaceuticals' official website?

The official website for Conatus Pharmaceuticals is www.conatuspharma.com.

How can I contact Conatus Pharmaceuticals?

Conatus Pharmaceuticals' mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.